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ABSTRACT 
Unfortunately, at present, degenerative retinal diseases such as retinitis pigmentosa remains untreatable. 
Patients with these conditions suffer progressive visual decline resulting from continuing loss of 
photoreceptor cells and outer nuclear layers. However, stem cell therapy is a promising approach to 
restore visual function in eyes with degenerative retinal diseases such as retinitis pigmentosa. Animal 
studies have established that pluripotent stem cells when placed in the mouse retinitis pigmentosa models 
have the potential not only to survive, but also to differentiate, organize into and function as 
photoreceptor cells.  Furthermore, there is early evidence that these transplanted cells provide improved 
visual function. These groundbreaking studies provide proof of concept that stem cell therapy is a viable 
method of visual rehabilitation among eyes with retinitis pigmentosa. Further studies are required to 
optimize these techniques in human application. This review focuses on stem cell therapy as a new 
approach for vision restitution in retinitis pigmentosa. 
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INTRODUCTION 
At present, degenerative retinal diseases such as retinitis 
pigmentosa (RP) and dry type age related macular 
degeneration (AMD) remain untreatable.  Patients with 
these conditions suffer progressive visual decline 
resulting from continuing loss of photoreceptor cells and 
outer nuclear layers.  Both disorders are characterized by 
the progressive dysfunction and death of the light 
sensing photoreceptors of the retina and other 
supportive cells. Because of the limited regenerative 
capacity of the mammalian retina, retinal progenitor cell 
are being developed to serve as “spare parts” for lost 
photoreceptor cells.  Advances in molecular biology have 
identified innovative approaches that, for the first time, 
provide hope for permanent visual rehabilitation.   Stem 
cell therapy can potentially replace lost photoreceptor 
and retinal pigment epithelial cell and subsequently 
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restore visual function in eyes with degenerative retinal 
disorders [1]. 
 
HYPOTHESIS 
A potential target disease for stem cell therapy is retinitis 
pigmentosa (RP). RP is the most commonly inheritable 
eye disease that causes progressive loss of 
photoreceptor cells resulting in gradual visual decline. 
While the onset of RP  may occur during infancy, the first 
symptoms are usually observed in early adulthood, 
beginning with nyctalopia or night blindness followed by 
loss of peripheral vision and eventually, as the central 
photoreceptors in the macula are damaged, loss of fine 
central vision.   Morphologically, these retinas are 
characterized by centripetal proliferation of bone 
spicule-like pigmentation, attenuation of retinal blood 
vessels and optic nerve pallor (Figure 1). At least 50 
genetic mutations have been associated with the 
disease.  The Beijing Eye Study reported a prevalence 
rate of 1 in 1000 and estimates about 1.3 million people 
are afflicted in China alone [2]. 
Transplantation of progenitor stem cells that can be 
stimulated to become replacement photoreceptors and 
supportive outer retina cells can theoretically lead to 
treatments that restore visual function [3]. Recently, the 
U.S. Food and Drug Administration approved phase I/II 
clinical trials for stem cell-based retinal pigmented 
epithelium (RPE) transplantation. Several issues 
surrounding stem cell use need to be addressed.   When 
is stem cell therapy indicated?  What type of stem cells 
to use and at what dosage?  How to safely implant into 
the target tissues?  How to efficiently stimulate stem 
cells into the desired development pathway?  What are 
the side effects? What is the duration of effect? This 
article will review some of the developments in this field 
of regenerative medicine for the treatment of 
degenerative retinal diseases.   
 
DISCUSSION 
Two types of stem cells may be utilized to produce 
retinal progenitor cells. Firstly, Embryonic stem (ESC) and 
secondly, induced pluripotent stem (IPS) cells.  Both 
types of cells are pluripotent and capable of becoming 
any cell type.  ESC’s are derived from embryos while IPS 
cells are obtained from a variety of adult tissues such as 
skin, bone marrow, teeth.  IPS cells, if successfully 
implanted and optimized, can potentially provide an 
unlimited supply of stem cells for transplantation.   
Cell replacement is one approach for restoration of vision 
in RP.  Because visual loss usually occurs when the outer 
retinal photoreceptor layer is lost, therapeutic timing 
should be at this stage of disease. Singh and colleagues 
have demonstrated using a murine model of severe 
human retinitis pigmentosa, that at a stage when no host 
rod cells are remaining, transplanted rod precursors can 
reestablish an anatomically distinct and appropriately 
polarized outer nuclear layer.  In their study, restoration 
of a trilaminar retinal organization was restored to RD1 
hosts with only two retinal layers before treatment. The 
introduced rod precursors continued to develop in the 
host niche to become mature rods complete with light-
sensitive outer segments and connections to host 
neurons downstream.  Visual function was also restored.  
These findings indicated that stem cell therapy may 
reinstate a light-sensitive cell layer de novo and restore 
structurally damaged visual circuits.  In this model, total 
photoreceptor layer reconstruction is one approach to 
further develop cell-based strategies for retinal repair 
[4]. 
 
 
 
Figure 1: Fundus photograph of eye with advanced retinitis pigmentosa.  
Note encroachment of the pigmentation into the macula, patchy loss of 
retinal pigment epithelial layers, attenuation of retinal blood vessels 
and optic nerve pallor. 
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ESC’s have been shown to generate functional 
photoreceptor cells restoring light response of 
photoreceptor-deficient mice, but there is concern over 
the risk for tumor formation using ESC.  Li and colleagues 
successfully cultured Nestin(+)Sox2(+)Pax6(+) 
multipotent retinal stem cells (RSCs) from the adult 
mouse retina.  These ESC’s are capable of producing 
functional photoreceptor cells that restore light response 
of photoreceptor-deficient RD1 mutant mice. After 
several cycles of expansion using growth factors, cultured 
RSCs still maintained proliferation and differentiation 
potential [5]. 
Under optimized differentiation conditions, ESC’s can 
differentiate into all the major retinal cell types found in 
the adult retina such as photoreceptor cells under 
optimized differentiation conditions. Following 
transplantation into the subretinal space of slowly 
degenerating RD7 mutant eyes, RSC-derived 
photoreceptor cells were shown to integrate into the 
retina, and develop into cells morphologically resembling 
endogenous photoreceptors and forming synapses with 
resident retinal neurons.  When transplanted into eyes of 
photoreceptor-deficient RD1 mutant mice, an RP model, 
RSC-derived photoreceptors can partially restore light 
response, indicating functionality. In animal studies, no 
evidence for tumor development was found [5].   
Along similar lines, autologous IPS cells are being 
developed for stem cell transplantation. This lack of 
immunogenicity confers an important advantage. 
Because IPS cells are autologous or derived from the 
same organism, they do not incite immunological 
reaction nor require use of immunosuppressive 
medication [6].   
Li  and colleagues recently transplanted human IPS cell-
derived retinal pigment epithelium (RPE) cells into the 
subretinal spaces of  mouse models with the Rpe65rd12 
/Rpe65rd12 form of RP. A healthy adult provided skin 
fibroblasts cultured with lentivirus-delivered genes 
encoding transcription factors OCT4, SOX2, KLF4, and 
MYC. Antibody staining of markers (TRA-1-60, SSEA4, 
NANOG, and SOX2) and a teratoma assay demonstrated 
pluripotency of the hiPS cells. Culturing in differentiation 
medium guided their fate to RPE. By 12 weeks, from 30% 
to 50% of the surfaces of 12-well dishes were coated 
with RPE with characteristic hexagonal shapes, 
perinuclear melanin granules, and microvilli [6].  
The target mice had albinism, which provided a white 
contrast against which the transplanted pigmented cells 
would be visible. The mice also had severe combined 
immune deficiency to prevent graft-vs-host disease.  An 
injection of 1000 hiPS-derived RPE cells was administered 
into the subretinal space in the right eyes of 34 mice at 
two days following birth. The mice were sacrificed at six 
months, shortly before they would have died from 
severe combined immune deficiency [6]. 
Successful development into RPE cells was indicated by: 
1) microscopic confirmation of pigmented hiPS-derived 
RPE admixed into the native, albino RPE; 2) quantitative 
polymerase chain reaction detection of markers of 
human fetal RPE and IPS-derived RPE; 3) positive staining 
for rhodopsin indicating that the hiPS-derived RPE cells 
phagocytosed photoreceptors.  Furthermore,  in some 
mice, electroretinogram (ERG) response to measure 
neuronal function, demonstrated   a small but significant 
improvement of mean β-wave peak difference between 
treated and control eyes of  13.7 μV (P = 0.0246).   
Furthermore, no tumor growth was observed [6].    
The use of retinal progenitor sheet transplantation is 
another promising approach. Seller and Aramant 
demonstrated that when freshly dissected sheets of 
fetal-derived retinal progenitor cells are mixed with RPE 
and transplanted subretinally, improvements of visual 
acuity are observed among animals and humans.  Visual 
improvement in this model is attributed to restoration of 
synaptic connections between transplant and host when 
transplant processes proliferate into the inner plexiform 
layer of the host retina and presumably form synapses.  
One drawback of widespread use of this method is 
limited supply of fetal donor tissue [7]. 
Future areas for stem cell development include methods 
for optimizing stem cell production and delivery.  The use 
of specific extracellular matrix can stimulate the 
development of human pluripotent stem cells into 
transient organized neuroepithelum with rapid 
differentiation into retinal progenitor cells [8]. Garit-
Hernandez and colleagues reported that by replicating 
the hypoxic stages of retinal development, an increase in 
number of retinal cells (Crx-positive, S-Opsin-positive, 
rhodopsin/recoverin positive cells) derived from ESC 
transplanted in the subretinal space of wild type mice 
[9]. Some promising work has been reported on 
increasing the yield of differentiated rod photoreceptor 
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genes by using the conjunctiva mesenchymal stem cells 
on nanofibrous scaffolds [10]. 
 
CONCLUSION 
Previously, RP was considered a devastating and 
untreatable condition. These pioneering animal studies 
provide hopeful evidence for the hypothesis that stem 
cell therapy is a viable means for visual rehabilitation of 
RP patients. What is now known is that stem cell therapy 
can potentially replace degenerate photoreceptors and 
outer retinal cells. When placed in the appropriate tissue 
niche, these stem cells not only survive but differentiate 
into critical retinal cells, develop a retina-like 
organizational structure and exhibit functional 
characteristics of full-fledged photoreceptors and outer 
retinal cells.  Further studies are needed to optimize 
techniques and validate these findings before proceeding 
to human trials.   
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